The plant in Moscow has significantly increased the production of essential medicines

Capital enterprises of the pharmaceutical industry with the support of the city authorities are modernizing their capacities and increasing the production of modern domestic drugs. In particular, the company "Binnofarm" for the first nine months of 2026 significantly increased the production of drugs for the treatment of asthma, chronic viral hepatitis and other diseases. This was announced by the Minister of the Government of Moscow, head of the Department of Investment and Industrial Policy of Moscow Anatoly Garbuzov.

“In total, in January-September of this year, about 4 million packages of medicines were created at the production site of the Moscow plant,” Garbuzov said.

In particular, according to the data of the beginning of October 2026, the production of an inhaled drug for basic therapy of bronchial asthma increased by 80%, reaching 124 thousand packages, the manufacture of a drug used for chronic viral hepatitis B and C, as well as for a number of oncological diseases, during this period the plant produced 54.4 thousand packages of this product increased by 5.7 times. In addition, the production of the drug for the treatment of proctological diseases increased by 10.6% to 455 thousand packages, and the production of local anesthesia for surgical interventions increased by 57%, which corresponds to 23.8 thousand packages.

According to Maria Bezrukova, Executive Director of Binnofarm, the production indicators are the needs of patients in high-quality and necessary therapy. “By increasing the production of drugs, we are contributing to the provision of medicines to people with chronic diseases, for whom it is important to receive treatment in a timely manner and without interruption,” she added.

The Binnofarm plant is a biotechnological site of Binnofarm Group and has the status of an industrial complex, which gives it access to significant tax benefits. The company actively invests in the development of production.

Earlier, Anatoly Garbuzov at a press conference said that the pharmaceutical industry has become one of the branches of the capital industry, which showed growth in the first nine months of this year. According to him, the production of medicines in Moscow increased by 3.4% compared to the three quarters of 2025. The production of drugs for the treatment of respiratory organs increased the most – by 36.3%. The production of drugs for the cardiovascular system increased by 26.4%, drugs that affect blood and blood - by 26.3%, drugs for the treatment of the nervous system - by 5%. Capital enterprises also produce drugs for the treatment of cancer and diabetes, painkillers, antibiotics and vaccines.

According to Garbuzov, at the moment there are more than 100 pharmaceutical enterprises in the capital, which employ about 17,000 people. In total, 4,740 industrial companies operate in Moscow, employing 767,000 people. Manufacturers have access to more than 20 effective support measures, including an investment loan interest reimbursement program, tax incentives and other instruments. At the same time, about 150 high-tech enterprises are opened in the city annually.